January 25, 2013: Gilead Sciences wins funding to train front-line manufacturing workers at its San Dimas GMP facility to produce medicines to treat (HIV)/AIDS, liver diseases and respiratory conditions.

Contact: Duval Capozzi
Sr. Manager, Quality Training
Gilead Sciences
650 Cliffside Drive
San Dimas, CA 91773
ETP Funding: Open ended 

Founded in 1987 and based in Foster City, Gilead is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead’s products improve the care of patients suffering from human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. Gilead reports that a majority of its revenue was for HIV products but the company also manufactures the anti-influenza drug Tamiflu and hepatitis B antiviral Hespera. In addition, Gilead is in the process of conducting clinical trials for the treatments for resistant hypertension, cystic fibrosis, HIV, and hepatitis.

The manufacture of Gilead’s products is a highly exacting and complex process due in part to strict regulatory requirements imposed by the Food and Drug Administration (FDA) and other foreign regulatory agencies where Gilead’s products are sold. To be successful, Gilead must have an experienced, well trained, workforce that can understand and follow specific quality protocols and manufacturing procedures. While at the same time, work efficiently and contribute to the high work standards required by the biotech industry. Therefore, Gilead is proposing to train 125 currently employed, front-line employees and 75 newly hired, front-line manufacturing workers at its California locations but a majority of the training will occur at its San Dimas facility.